1. Home
  2. CLWT vs VCNX Comparison

CLWT vs VCNX Comparison

Compare CLWT & VCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLWT
  • VCNX
  • Stock Information
  • Founded
  • CLWT 1971
  • VCNX 2001
  • Country
  • CLWT Hong Kong
  • VCNX United States
  • Employees
  • CLWT N/A
  • VCNX N/A
  • Industry
  • CLWT Professional and commerical equipment
  • VCNX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CLWT Consumer Discretionary
  • VCNX Health Care
  • Exchange
  • CLWT Nasdaq
  • VCNX Nasdaq
  • Market Cap
  • CLWT 11.2M
  • VCNX 10.5M
  • IPO Year
  • CLWT 1997
  • VCNX N/A
  • Fundamental
  • Price
  • CLWT $1.40
  • VCNX $1.41
  • Analyst Decision
  • CLWT
  • VCNX
  • Analyst Count
  • CLWT 0
  • VCNX 0
  • Target Price
  • CLWT N/A
  • VCNX N/A
  • AVG Volume (30 Days)
  • CLWT 8.9K
  • VCNX 96.1K
  • Earning Date
  • CLWT 12-20-2024
  • VCNX 11-14-2024
  • Dividend Yield
  • CLWT 5.56%
  • VCNX N/A
  • EPS Growth
  • CLWT 395.79
  • VCNX N/A
  • EPS
  • CLWT 0.24
  • VCNX N/A
  • Revenue
  • CLWT $17,940,000.00
  • VCNX $388,000.00
  • Revenue This Year
  • CLWT N/A
  • VCNX N/A
  • Revenue Next Year
  • CLWT N/A
  • VCNX N/A
  • P/E Ratio
  • CLWT $6.09
  • VCNX N/A
  • Revenue Growth
  • CLWT 20.01
  • VCNX N/A
  • 52 Week Low
  • CLWT $1.28
  • VCNX $1.25
  • 52 Week High
  • CLWT $1.94
  • VCNX $13.02
  • Technical
  • Relative Strength Index (RSI)
  • CLWT 41.60
  • VCNX 27.23
  • Support Level
  • CLWT $1.34
  • VCNX $3.34
  • Resistance Level
  • CLWT $1.49
  • VCNX $4.35
  • Average True Range (ATR)
  • CLWT 0.08
  • VCNX 0.45
  • MACD
  • CLWT 0.00
  • VCNX -0.19
  • Stochastic Oscillator
  • CLWT 47.06
  • VCNX 0.00

About CLWT Euro Tech Holdings Company Limited

Euro Tech Holdings Co Ltd is a distributor and manufacturer of technology instruments as well as an environmental engineering services provider. It is engaged in the marketing and trading of water and wastewater related process control, analytical and testing instruments, disinfection equipment, supplies, and related automation systems. There are two operating segments of the company. The Trading and manufacturing segment, which is the key revenue driver, includes distribution of water treatment equipment, laboratory instruments, analyzers, test kits, and related supplies and power generation equipment. The Engineering segment includes water and waste-water treatment engineering and air pollution control business. The majority of the revenue is generated from Hong Kong.

About VCNX Vaccinex Inc.

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Share on Social Networks: